| 0.527 0.069 (15.07%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.64 |
1-year : | 0.74 |
| Resists | First : | 0.54 |
Second : | 0.64 |
| Pivot price | 0.42 |
|||
| Supports | First : | 0.45 |
Second : | 0.38 |
| MAs | MA(5) : | 0.45 |
MA(20) : | 0.43 |
| MA(100) : | 0.34 |
MA(250) : | 0.74  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 73.2 |
D(3) : | 60.5 |
| RSI | RSI(14): 69.7 |
|||
| 52-week | High : | 2.75 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ENSC ] has closed Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.55 | 0.55 - 0.55 |
| Low: | 0.48 - 0.48 | 0.48 - 0.48 |
| Close: | 0.52 - 0.53 | 0.53 - 0.53 |
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Fri, 02 Oct 2026
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Tue, 29 Sep 2026
ENSC Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 20 Aug 2026
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Tue, 18 Aug 2026
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Tue, 18 Aug 2026
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Fri, 14 Aug 2026
ENSC Sets Itself Up Nicely for Critical Stage - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 1.854e+007 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -280.5 % |
| Operating Margin | -221.3 % |
| Return on Assets (ttm) | -185.6 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 4.5e+006 % |
| Gross Profit (p.s.) | -14.81 |
| Sales Per Share | 289.3 |
| EBITDA (p.s.) | -7.73529e+006 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.76 |
| Dividend | 0 |
| Forward Dividend | 1.08e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|